オプションチェーンは、Theriva Biologicsの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Theriva Biologicsの市場センチメントを評価します。.

Theriva Biologics (AMEX:TOVX) 株価情報, オプションチェーン

Theriva Biologics

Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.

Theriva Biologics Inc

BT Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTBD#NASDAQ">BTBD</a>) reported quarterly losses of $(0.05) per share. This is a 28.57 percent increase over losses of $(0.07) per share from the same period last year. The company reported $3.23 million in sales this quarter. This is a 1.28 percent increase over sales of $3.19 million the same period last year.

Earnings

News

BTBD

BT Brands Q1 EPS $(0.05) Up From $(0.07) YoY, Sales $3.23M Up From $3.19M YoY

The quarterly cash dividend amount of $0.18 per share will be paid on June 16, 2025, to shareholders of record at the close of business on May 30, 2025.

Dividends

Advanced Drainage Systems Raises Annual Dividend By 13% To $0.72 Per Share; Sets $0.18 Quarterly Payout For June 16

Needham analyst Gil Blum reiterates Celcuity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELC#NASDAQ">CELC</a>) with a Buy and maintains $29 price target.

Price Target

Reiteration

Analyst Ratings

CELC

Needham Reiterates Buy on Celcuity, Maintains $29 Price Target

Citigroup analyst John Yu initiates coverage on Webtoon Entertainment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBTN#NASDAQ">WBTN</a>) with a Buy rating and announces Price Target of $11.

Initiation

WBTN

Citigroup Initiates Coverage On Webtoon Entertainment with Buy Rating, Announces Price Target of $11

GPUS

Hyperscale Data Plans To Resume Bitcoin Mining Operations At One Of Its Two Montana Sites On Or Around June 10, 2025

Quarterhill (TSX:<a class="ticker" href="https://www.benzinga.com/stock/QTRH#TSX">QTRH</a>) reported quarterly losses of $(0.07) per share. This is a 75 percent decrease over losses of $(0.04) per share from the same period last year. The company reported $33.89 million in sales this quarter. This is a 2.89 percent decrease over sales of $34.90 million the same period last year.

TSX:QTRH

Quarterhill Q1 EPS $(0.07) Down From $(0.04) YoY, Sales $33.89M Down From $34.90M YoY

Needham analyst Laura Martin reiterates Roku (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>) with a Buy and maintains $88.5 price target.

ROKU

Needham Reiterates Buy on Roku, Maintains $88.5 Price Target

Fiscal Year 2026 Outlook
Based on current visibility, backlog of existing orders and business trends, the Company issued the following targets for fiscal 2026. Net sales are expected to be in the range of $2.825 billion to $2.975 billion. Adjusted EBITDA is expected to be in the range of $850 million to $910 million. Capital expenditures are expected to be approximately $275 million.

Guidance

Advanced Drainage Systems Sees FY2026 Sales $2.825B-$2.975B Vs. $3.07B Est

NACCO Industries&#xAE; (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NC#NYSE">NC</a>) announced today that its Board of Directors declared a regular quarterly cash dividend of 25.25 cents per share, which represents an 11% increase compared to the prior quarterly dividend rate of 22.75 cents per share. The dividend is payable on both the Class A and Class B Common Stock, and will be paid June 16, 2025 to stockholders of record at the close of business on May 30, 2025. The new dividend is equal to an annual rate of $1.01 per share, up 10 cents from the prior annual rate of $0.91 per share. This represents NACCO's seventh consecutive annual dividend increase since the dividend was reset following the spin-off of Hamilton Beach Brands Holding Company in September 2017. NACCO and its predecessor companies have paid quarterly cash dividends to stockholders since 1956.

NACCO Industries Raises Quarterly Cash Dividend 11% From $0.23 To $0.25 Per Share

JP Morgan analyst Samik Chatterjee downgrades Luminar Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LAZR#NASDAQ">LAZR</a>) from Overweight to Neutral.

Downgrades

LAZR

JP Morgan Downgrades Luminar Technologies to Neutral

On the Acquired podcast, Nvidia Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) CEO Jensen Huang made a frank admission: if he were 30 years of age again, he would not start his own company. Despite NVIDIA's record-breaking success, Huang revealed his feelings about the <a href="https://www.benzinga.com/markets/25/05/45243129/nvidia-ceo-jensen-huang-says-losing-access-to-chinas-potential-50-billion-ai-market-would-be-a-tremendous-loss">challenging parts</a> of the journey.
What Happened: When asked what kind of company he would create if given another chance, Huang responded, "I wouldn't do it."
"Building a company and building Nvidia turned out to have been a million times harder than any of us expected it to be. And at the time, if we realized the pain and suffering and just how vulnerable you're going to feel and the challenges that you're going to endure, the embarrassment and the shame, and the list of all the things that go wrong—I don't think anybody would start a company. Nobody in their right mind would do it," Huang added. 
See Also: <a href="https://www.benzinga.com/media/25/05/45426637/nvidia-ceo-jensen-huang-expected-to-unveil-new-ai-alliances-at-computex-2025-as-geopolitical-pressures-persist-over-tech-sector">Nvidia CEO Jensen Huang Expected To Unveil New AI Alliances At Computex 2025 As Geopolitical Pressures Persist Over Tech Sector</a>
Why It Matters: Huang noted that most founders achieve success because they underestimate the difficulty at the beginning. "You have to get yourself to believe that it's not that hard because it's way harder than you think…Taking all of my knowledge now—I go back, and I said I'm going to endure that whole journey again, I think it's too much. It is just too much.&#8221;
He also highlighted the importance of a robust support network. "You need the unwavering support of the people around you… I'm pretty sure that almost every successful company and entrepreneurs that have gone through some difficult challenges had that support system around them."
Despite these challenges, Huang's company continues to make waves, with Nvidia projected to <a href="https://www.benzinga.com/news/large-cap/25/05/45414265/nvidia-climbs-on-saudi-ai-investments-analyst-estimates-15-billion-to-20-billion-in-revenue">generate billions in revenue</a> from newly announced investments from Saudi Arabia. On Tuesday, President Donald Trump praised Huang for controlling "99% of the chip market" during the <a href="https://www.benzinga.com/markets/equities/25/05/45398595/trump-praises-nvidia-ceo-jensen-huang-at-saudi-summit-tim-cook-isnt-here-but-you-are-controlling-99-of-the-chip-market-thats-not-easy-to-beat">U.S.-Saudi Investment Forum</a>, spotlighting the company's planned $500 billion investment in U.S. artificial intelligence infrastructure.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="NVIDIA CEO Jensen Huang" width="500" height="281" src="https://www.youtube.com/embed/y6NfxiemvHg?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/05/45430137/trump-had-a-problem-with-tim-cook-president-says-he-told-apple-ceo-i-dont-want-you-building-in-india-amid-tariff-concerns-and-production-shift-from-china">Trump Had A &#8216;Little Problem&#8217; With Apple CEO Tim Cook, Says &#8216;I Don&#8217;t Want You Building In India&#8217;</a></li>
</ul>
Image Via Shutterstock

Success Stories

NVDA

Jensen Huang Says He Wouldn't Start Nvidia Again If He Were 30, Calling The Journey 'Too Much' Despite the Company's Massive Success

BiomX (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PHGE#AMEX">PHGE</a>) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0.42) by 21.43 percent. This is a 88.21 percent increase over losses of $(2.80) per share from the same period last year.

Earnings Beats

PHGE

BiomX Q1 EPS $(0.33) Beats $(0.42) Estimate

Advanced Drainage Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMS#NYSE">WMS</a>) reported quarterly earnings of $1.03 per share which missed the analyst consensus estimate of $1.10 by 6.36 percent. This is a 16.26 percent decrease over earnings of $1.23 per share from the same period last year. The company reported quarterly sales of $615.76 million which missed the analyst consensus estimate of $653.22 million by 5.73 percent. This is a 5.82 percent decrease over sales of $653.84 million the same period last year.

Earnings Misses

Advanced Drainage Systems Q4 Adj. EPS $1.03 Misses $1.10 Estimate, Sales $615.76M Miss $653.22M Estimate

Jefferies analyst Alejandro Demichelis upgrades Petrobras Brasileiro (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBR#NYSE">PBR</a>) from Hold to Buy and announces $15.3 price target.

Upgrades

Jefferies Upgrades Petrobras Brasileiro to Buy, Announces $15.3 Price Target

BABA

UPDATE: Alibaba Reported A 76% Drop in Free Cash Flow to $516M in Q1 2025 Due to Higher Cloud Infrastructure Spending

DA Davidson analyst Keegan Cox assumes Hasbro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HAS#NASDAQ">HAS</a>) with a Neutral rating and maintains Price Target of $75.

DA Davidson Assumes Hasbro at Neutral, Maintains Price Target of $75

Net income attributable to Deere &amp; Company for fiscal 2025 is forecasted to be in a range of $4.75&nbsp;billion to $5.50 billion.
 &nbsp;

Deere & Co Expects FY25 Net Income Of $4.75B-$5.50B

Needham analyst Mayank Tandon maintains Endava (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAVA#NYSE">DAVA</a>) with a Buy and lowers the price target from $22 to $18.

DAVA

Needham Maintains Buy on Endava, Lowers Price Target to $18

Deere Q2 EPS $6.64 Beats $5.59 Estimate, Sales $12.76B Beat $10.79B Estimate

Biotech

Health Care

Financing

Offerings

General

AURA

Aura Biosciences Has Launched An Underwritten Public Offering Of Shares And Accompanying Warrants, Details Undisclosed

Press Releases

Theriva™ Biologics Announces U.S. FDA Guidance on Design of Phase 3 Study of VCN-01 for the Treatment of Metastatic Pancreatic Cancer

Theriva™ Biologics to Participate in the Q1 Investor Summit Virtual

Theriva™ Biologics Reports Full-Year 2024 Operational Highlights and Financial Results

Theriva™ Biologics to Present at the 2025 NeauxCancer Conference

Theriva™ Biologics Announces Positive Outcomes from the Second Meeting of the Independent Data Monitoring Committee for VIRAGE, the Company's Phase 2b Clinical Trial of VCN-01 in Combination with Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

Theriva Biologics Announces Presentation of Data from the Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients

Theriva™ Biologics Announces Primary Endpoints for Efficacy and Safety Achieved in VIRAGE Phase 2b Clinical Trial of VCN-01 with Gemcitabine/nab-Paclitaxel in Newly-Diagnosed Metastatic Pancreatic Cancer Patients

Theriva Biologics Announces Pricing of $7.5 Million Public Offering

Theriva Biologics Announces Closing of $7.5 Million Public Offering

Theriva™ Biologics Reports First Quarter 2025 Operational Highlights and Financial Results

TOVX

Aditxt

Apollomics

Aptevo Therapeutics

Bone Biologics

Entero Therapeutics

Genprex

GRI Bio

Pasithea Therapeutics Corp. - Common Stock

Pasithea Therapeutics

NuCana

Onconetix

Psyence Biomedical Ltd. - Ordinary Shares

Psyence Biomedical

Polyrizon

Protagenic Therapeutics, Inc. - Common Stock

Protagenic Therapeutics

Scinai Immunotherapeutics Ltd. - American Depositary Shares

Scinai Immunotherapeutics

Shuttle Pharmaceuticals Holdings, Inc. - common stock

Shuttle Pharmaceuticals

Salarius Pharmaceuticals, Inc. - Common Stock

Salarius Pharmaceuticals

Tharimmune

ZyVersa Therapeutics, Inc. - Common Stock

ZyVersa Therapeutics

Screenshot 2024-08-23 at 5.34.20 PM

Theriva Biologics Receives Rare Pediatric Drug Designation From FDA For Treatment Of Retinoblastoma

Screenshot 2024-07-31 at 5.25.33 PM

Theriva Biologics Advances Its Product Pipeline To Improve Survival Rates For Many Difficult-To-Treat Cancers

Screenshot 2024-07-08 at 2.14.39 PM

Disproportionate Rise In Pancreatic Cancer Among Young Women Highlights High Unmet Need To Find Safe, Effective Treatments – Is Hope On The Horizon?

Screenshot 2024-06-06 at 5.27.01 PM

Theriva Biologics Receives Fast Track Designation From FDA For VCN-01 For Treating Metastatic Pancreatic Cancer

Screenshot 2024-04-16 at 5.31.31 PM

Theriva Biologics Hits Several Milestones In 2023, Positioning Itself For Growth As The Firm Targets Difficult-To-Treat Cancers

Screenshot 2024-03-26 at 11.16.22 PM

Utilizing Common Viruses To Combat Dangerous Cancers – Hear From The Leaders Of This Biotech

Screenshot 2024-03-13 at 5.34.18 PM

How Theriva Biologics Is Using An Adenovirus To Develop A Novel Treatment For Pancreatic Cancer, As Well As Other Cancers With An Unmet Need

Screenshot 2024-03-05 at 6.31.45 PM

CADL

CGON

CLDI

Could This Common Virus Unlock New Cancer Treatments? Theriva Biologics Believes That Adenoviruses Could Be Instrumental In The Next Evolution Of Oncology

Screenshot 2024-02-28 at 6.54.06 PM

For The First Time The US Is Set To Hit 2 Million New Cancer Cases: Theriva Biologics Presents Novel Solutions To The Deadliest Cancers

Comments

Theriva Biologics

Theriva Biologics (TOVX) オプション

No option chain data available. Please try again later

ニュース

パートナーシップ

ベンジンガ・グローバル